Cargando…

Correction: M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way

Detalles Bibliográficos
Autores principales:	Li, Kai, Peng, Zi-Yang, Gao, Shan, Wang, Qing-Shi, Wang, Rui, Li, Xiang, Xiao, Guo-Dong, Zhang, Jing, Ren, Hong, Tang, Shou-Ching, Sun, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364362/ https://www.ncbi.nlm.nih.gov/pubmed/37488615 http://dx.doi.org/10.1186/s13046-023-02760-8

Ejemplares similares

M6A associated TSUC7 inhibition contributed to Erlotinib resistance in lung adenocarcinoma through a notch signaling activation dependent way
por: Li, Kai, et al.
Publicado: (2021)

Correction: MiR-129 blocks estrogen induction of NOTCH signaling activity in breast cancer stem-like cells
por: Xiao, Guodong, et al.
Publicado: (2023)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Correction to: Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
por: Wang, Chenwei, et al.
Publicado: (2022)

Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway
por: Zhang, Haiwei, et al.
Publicado: (2017)

Correction to: Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma
por: Chen, Yan, et al.
Publicado: (2021)

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma
por: Jiang, Shiyao, et al.
Publicado: (2022)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Blocking ROR1 enhances the roles of erlotinib in lung adenocarcinoma cell lines
por: Wang, Hui-Li, et al.
Publicado: (2019)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Correction: R54C Mutation of NOTCH3 Gene in the First Rungus Family with CADASIL
por: Lim, Kheng-Seang, et al.
Publicado: (2015)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase
por: Dong, Jiang-Kai, et al.
Publicado: (2018)

Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7
por: Li, Kai, et al.
Publicado: (2023)

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2(nd)/3(rd) Line Therapy in Patients with Lung Adenocarcinoma
por: He, Yayi, et al.
Publicado: (2016)

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum
por: Dong, Jiang-Kai, et al.
Publicado: (2021)

Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma
por: Kurishima, Koichi, et al.
Publicado: (2014)

MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Notch Signaling Components: Diverging Prognostic Indicators in Lung Adenocarcinoma
por: Liu, Zhi-Yan, et al.
Publicado: (2016)

Inhibition of miR-200b Promotes Angiogenesis in Endothelial Cells by Activating The Notch Pathway
por: Qiu, Tie-Ying, et al.
Publicado: (2022)

Correction: High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma
por: Zhang, Yixiang, et al.
Publicado: (2023)

Two ways to condense
por: Katsnelson, Alla
Publicado: (2007)

Correction: The effect of NOTCH3 pathogenic variant position on CADASIL disease severity: NOTCH3 EGFr 1–6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7–34 pathogenic variant
por: Rutten, Julie W., et al.
Publicado: (2018)

Advanced lung adenocarcinoma in an EGFR-positive patient treated with Erlotinib for 52 months
por: Gonçalves, Ivone, et al.
Publicado: (2013)

Correction to: The immunomodulatory functions and molecular mechanism of a new bursal heptapeptide (BP7) in immune responses and immature B cells
por: Feng, Xiu Li, et al.
Publicado: (2021)

Correction: Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor
por: Solanki, Hitendra S., et al.
Publicado: (2021)

Author Correction: The immunotherapy candidate TNFSF4 may help the induction of a promising immunological response in breast carcinomas
por: Li, Kai, et al.
Publicado: (2023)

Correction: Ethyl ferulate contributes to the inhibition of the inflammatory responses in murine RAW 264.7 macrophage cells and acute lung injury in mice
por: Wang, Yu, et al.
Publicado: (2022)

LncRNA‐DANCR contributes to lung adenocarcinoma progression by sponging miR‐496 to modulate mTOR expression
por: Lu, Qing‐chun, et al.
Publicado: (2017)

CSL–MAML-dependent Notch1 signaling controls T lineage–specific IL-7Rα gene expression in early human thymopoiesis and leukemia
por: González-García, Sara, et al.
Publicado: (2009)

Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review
por: Zheng, Hua, et al.
Publicado: (2016)

Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)
por: Yang, Haihong, et al.
Publicado: (2017)

Correction: LINC01152 upregulates MAML2 expression to modulate the progression of glioblastoma multiforme via Notch signaling pathway
por: Wu, Jianheng, et al.
Publicado: (2021)

Correction: Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6 - methyladenosine of Notch1
por: Gu, Chaohui, et al.
Publicado: (2023)

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
por: Wang, Xiaoyuan, et al.
Publicado: (2018)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

Design, Synthesis, and Antitumor Activity of Erlotinib Derivatives
por: Mao, Long-fei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3sp6rm5i0p85tlene3j5e3todn